OTC and ornithine carbamoyltransferase deficiency: Yang et al. illustrated the use of a dual AAV system to deliver the CRISPR/Cas9 technology, utilizing one vector to introduce SaCas9 and another to provide sgRNA targeting ornithine transcarbamylase (OTC) in mice with partial OTC deficiency, which affects the urea cycle in the liver [19].